Opportunity awaits those up to the challenge of developing transformative therapies across a broad range of debilitating diseases. Summary: Independent Project Programmer for major therapeutic area, and/or Project/Technical leader on non-clinical project requiring supervision and coordination of personnel. Ability to offer consulting, training and support to users on applications developed by internal systems group. Independent Statistical Reporting representative on major Apellis initiatives. Roles and Responsibilities: Essential Duties: Independent Therapeutic area lead Coordinates and manages timely creation, oversight, review, completion, and delivery of statistical programming activities and deliverables of projects via external staff oversight. Maintain efficient interfaces with internal and external customers Program Data Manager and the Program Statistician for high level strategic advice. Manage complex projects and establish therapeutic area programming strategies. Develop and comply with project / study standards and specifications following internal and regulatory guidelines and Apellis SOPs and values Develop resource plans as required to support headcount justifications, resource forecasting and allocations Lead programming efforts across the Hematology therapeutic area Responsible for all programming deliverables for the indication/therapeutic area across multiple studies. Supervises multiple Sr. Statistical Programmers Follow outsourcing strategy as defined within Development Operations and supervise all outsourced activities outsourced to CRO. Please note this job description is not designed to cover or contain a comprehensive listing of activities, duties or responsibilities that are required of the employee for this job. Duties, responsibilities and activities may change at any time with or without notice. Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company leading the way in complement science to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two C3-targeting medicines approved to treat four serious diseases. Breakthroughs for patients include the first-ever therapy for geographic atrophy, a leading cause of blindness, and the first treatment for patients 12 and older with C3G or primary IC-MPGN, two severe, rare kidney diseases. We believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit http://apellis.com or follow us on LinkedIn and X.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Mid Level